Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

While circulating tumor cell (CTC)–based detection of AR-V7 has been demonstrated to predict patient response to second-generation androgen receptor therapies, the rarity of AR-V7 expression in metastatic castrate-resistant prostate cancer (mCRPC) suggests that other drivers of resistance exist. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jae-Seung, Wang, Yugang, Henderson, James, Singhal, Udit, Qiao, Yuanyuan, Zaslavsky, Alexander B., Hovelson, Daniel H., Spratt, Daniel E., Reichert, Zachery, Palapattu, Ganesh S., Taichman, Russell S., Tomlins, Scott A., Morgan, Todd M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612010/
https://www.ncbi.nlm.nih.gov/pubmed/31276932
http://dx.doi.org/10.1016/j.neo.2019.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612010/
https://www.ncbi.nlm.nih.gov/pubmed/31276932
http://dx.doi.org/10.1016/j.neo.2019.06.002

Ejemplares similares